A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Luckily for you, StockStory helps you navigate which companies are truly worth holding. Keeping that in mind, here are three low-volatility stocks that don’t make the cut and some better opportunities instead.
CONMED (CNMD)
Rolling One-Year Beta: 0.84
With over five decades of experience in surgical innovation since its founding in 1970, CONMED (NYSE: CNMD) develops and manufactures medical devices and equipment for surgical procedures, specializing in orthopedic and general surgery products.
Why Does CNMD Give Us Pause?
- Underwhelming constant currency revenue performance over the past two years suggests its product offering at current prices doesn’t resonate with customers
- Smaller revenue base of $1.37 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Estimated sales growth of 1.9% for the next 12 months implies demand will slow from its two-year trend
At $47.13 per share, CONMED trades at 10x forward P/E. Check out our free in-depth research report to learn more about why CNMD doesn’t pass our bar.
IQVIA (IQV)
Rolling One-Year Beta: 0.85
Created from the 2016 merger of Quintiles (a clinical research organization) and IMS Health (a healthcare data specialist), IQVIA (NYSE: IQV) provides clinical research services, data analytics, and technology solutions to help pharmaceutical companies develop and market medications more effectively.
Why Does IQV Worry Us?
- Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 5.6% over the last five years was below our standards for the healthcare sector
- Adjusted operating margin failed to increase over the last two years, indicating the company couldn’t optimize its expenses
- Free cash flow margin was stuck in limbo over the last five years
IQVIA’s stock price of $266.84 implies a valuation ratio of 19.2x forward P/E. Dive into our free research report to see why there are better opportunities than IQV.
Fidelity National Financial (FNF)
Rolling One-Year Beta: 0.43
Issuing more title insurance policies than any other company in the United States, Fidelity National Financial (NYSE: FNF) provides title insurance and escrow services for real estate transactions while also offering annuities and life insurance through its F&G subsidiary.
Why Do We Think FNF Will Underperform?
- Net premiums earned contracted by 3.8% annually over the last five years, showing unfavorable market dynamics this cycle
- Earnings per share fell by 5.5% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
- Products and services are facing significant credit quality challenges during this cycle as book value per share has declined by 2.1% annually over the last five years
Fidelity National Financial is trading at $39.72 per share, or 1.1x forward P/B. Read our free research report to see why you should think twice about including FNF in your portfolio.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
